Therapeutics Thursday (SCSS): Out of this World: Hemgenix® (etranacogene dezaparvovec), the Recently Approved Gene Therapy for Hemophilia B and the Most Expensive Drug in the World!

Hemophilia B, also known as factor IX deficiency, is the second most common type of hemophilia. This podcast will discuss the limitations of current therapeutic options for Hemophilia B and explore the use of the new gene therapy, Hemgenix® (etranacogene dezaprarvovec), the most expensive drug in the world, from both a clinical and cost perspective.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.